الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 237 |  |  |
| | | from | 237 | | |
Abstract
Schistosomiasis is a debilitating infectious disease which remains a public health problem in several parts of the world. It is caused by the parasitic flatworm Schistosoma. Individuals are infected when exposed to infested water during agricultural, domestic and occupational activities. Hepatic schistosomiasis, caused by Schistosoma mansoni (S. mansoni), is characterized by chronic fibrosis induced during the healing of the granulomata. It leads to human disabilities and decreased socioeconomic state and quality of life.
Praziquantel is the gold standard chemotherapeutic agent. Aside from its advantages, it has low affinity against the immature stages and the emergence of strains with reduced susceptibility minimizes its efficiency. Thereby, there is an urgent need for development of new anti-schistosomal alternatives. As the discovery of new lead drugs is an exhausting, time-consuming, and expensive process, the repurposing of approved drugs becomes an attractive way to overcome these obstacles. It has been recommended as a rapid, cheap and successful way for alternative drug discovery.
Celecoxib, the approved non-steroidal anti-inflammatory drug, exerts multiple pharmacologic activities including anti-neoplastic, anti-viral, anti-fungal and anti-bacterial activities through several mechanisms of action. It has well defined effects on essential organelles involved in cellular calcium homeostasis, biological enzymes and signals. In addition, it has high lipophilicity.